Viral quasi-species evolution during hepatitis Be antigen seroconversion

Gastroenterology. 2007 Sep;133(3):951-8. doi: 10.1053/j.gastro.2007.06.011. Epub 2007 Jun 20.

Abstract

Background & aims: Although viral quasi-species evolution may be related to pathogenesis of disease, little is known about this in hepatitis B virus (HBV); consequently, we aimed to evaluate the evolution of HBV quasi-species in patients with well-characterized clinical phenotypes of chronic hepatitis B.

Methods: Four cohorts of well-defined clinical phenotypes of chronic hepatitis B, hepatitis Be antigen (HBeAg) seroconverters (spontaneous seroconverters and interferon-induced seroconverters) and nonseroconverters (controls and interferon nonresponders) were followed during 60 months on average. Serum from 4 to 5 time points was used for nested polymerase chain reaction, cloning, and sequencing of the precore/core gene (20 clones/sample). Only patients with genotype B were used. Sequences were aligned using Clustal X, then serial-sample unweighted pair grouping method with arithmetic means phylogenetic trees were constructed using Pebble 1.0 after which maximum likelihood estimates of pairwise distances under a GTR + I + G model was assessed. Viral diversity and substitution rates were then estimated.

Results: Analysis of 3386 sequences showed that HBeAg seroconverters had 2.4-fold higher preseroconversion viral sequence diversity (P = .0183), and 10-fold higher substitution rate (P < .0001) than did nonseroconverters, who had persistently low viral diversity (3.6 x 10(-3) substitutions/site) and substitution rate (2.2 x 10(-5) substitutions x site(-1) x month(-1)). After seroconversion, there was a striking increase in viral diversity. Most seroconverters had viral variants that showed evidence of positive selection, which was seen mainly after seroconversion.

Conclusions: The high viral diversity before a reduction in HBV DNA and before HBeAg seroconversion could either be related to occurrence of stochastic mutations that lead to a break in immune tolerance or to increased immune reactivity that drives escape mutations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amino Acid Sequence
  • Antiviral Agents / therapeutic use
  • Base Sequence
  • Cohort Studies
  • DNA, Viral / genetics
  • Evolution, Molecular*
  • Female
  • Hepatitis B Antibodies / immunology*
  • Hepatitis B Antibodies / metabolism
  • Hepatitis B e Antigens / immunology*
  • Hepatitis B e Antigens / metabolism
  • Hepatitis B virus / classification*
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology*
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis B, Chronic / immunology
  • Hepatitis B, Chronic / virology*
  • Humans
  • Interferons / therapeutic use
  • Male
  • Mutation / genetics
  • Phenotype
  • Phylogeny
  • Viral Core Proteins / metabolism

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Antibodies
  • Hepatitis B e Antigens
  • Viral Core Proteins
  • Interferons